Overview

• US specialty pharma's fiscal 2025 product sales rose 50% yr/yr to record high

• Q4 product sales grew 75% yr/yr, reflecting increased PEDMARK adoption

• Company completed $42 mln equity offerings, ended year with no debt

Outlook

• Company did not provide specific financial guidance for upcoming quarters or full yr

Result Drivers

• PEDMARK ADOPTION - Co said record product sales growth was driven by increased PEDMARK adoption across new and existing accounts, including AYA patients and additional tumor types

• FIELD EXECUTION - Record patient enrollments and conversion rates in Q4 attributed to strong field execution, per management

• COMMERCIAL TEAM EXPANSION - Co expanded its customer-facing team in Q4 to accelerate growth and increase reach with oncology centers and AYA population

Company press release: ID:nGNX8DDMrH

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
FY Product Sales		$44.60 mln
FY Basic EPS		-$0.35

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Fennec Pharmaceuticals Inc is $15.50, about 108.1% above its March 23 closing price of $7.45

• The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 14 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.